Hemostatic Disorders D020141

Diseases [C] » Cardiovascular Diseases [C14] » Vascular Diseases » Hemostatic Disorders

Diseases [C] » Hemic and Lymphatic Diseases [C15] » Hematologic Diseases » Hemorrhagic Disorders » Hemostatic Disorders

Description

Pathological processes involving the integrity of blood circulation. Hemostasis depends on the integrity of BLOOD VESSELS, blood fluidity, and BLOOD COAGULATION. Majority of the hemostatic disorders are caused by disruption of the normal interaction between the VASCULAR ENDOTHELIUM, the plasma proteins (including BLOOD COAGULATION FACTORS), and PLATELETS.   MeSH

Subtype Terms (11)

Cryoglobulinemia
7 approved drugs

Ehlers-Danlos Syndrome
6 drugs (5 approved, 1 experimental)

Hemangioma, Cavernous
 

IgA Vasculitis
16 drugs (12 approved, 4 experimental)

Multiple Myeloma
860 drugs (291 approved, 569 experimental)

Pseudoxanthoma Elasticum
6 drugs (4 approved, 2 experimental)

Purpura, Hyperglobulinemic
 

Scurvy
1 approved drug

Shwartzman Phenomenon
 

Telangiectasia, Hereditary Hemorrhagic
17 drugs (14 approved, 3 experimental)

Waldenstrom Macroglobulinemia
171 drugs (92 approved, 79 experimental)


Other Experimental Indicated Drugs (1)


Hierarchy Tree View

UMLS Data


YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.